The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

UnitedHealth Group Inc. appointed Wayne DeVeydt to become chief financial officer, replacing longtime finance chief John Rex.

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Bain Capital and KKR are among three groups preparing bids for Sapporo Holdings' real estate business, valued at approximately $2.7 billion. Sapporo is selling its real estate hol ...

Bristol Myers Squibb (NYSE:BMY) and Bain Capital have announced the establishment of a new independent biopharmaceutical ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Backed by Bain Capital LP, the company has invited investment banks to pitch for roles in arranging the share sale, the ...